GSK bolsters respiratory pipeline with USD1.4 billion acquisition
(Alliance News) - GSK PLC's latest acquisition of Aiolos Bio Inc reflects its focus on respiratory diseases, with the latter's key asset potentially offering a chance to differentiate from rivals, Third Bridge noted. Read More